RxDoctor Payments DataLook up a doctor →

Qaiser Shafiq, MD

Interventional Cardiology · Southgate, MINPI 1225294168

Payments from drug & device makers

$1,338,738in general payments, 2019–2025

Across 762 payments — averaging $1756.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1M
  • Amgen$70K
  • Alnylam Pharmaceuticals Inc.$66K
  • Johnson & Johnson$42K
  • AstraZeneca$32K
  • Novartis$29K
  • plus $82K from 46 others
$298,262in research payments, 2019–2025

Across 2 payments — averaging $149,131 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$298K

What the payments were for

  • Consulting fees$4,0806%
  • Speaking & faculty fees$42,67563%
  • Travel & lodging$8,57313%
  • Food & beverage$12,09718%
  • Education$3541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,338,738 in reported general payments places this provider in the 95th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$590,744
Medicare patients
2,274
Services billed
6,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban483$513,367
EntrestoSacubitril/Valsartan352$464,836
UptraviSelexipag12$257,960
JardianceEmpagliflozin145$173,604
XareltoRivaroxaban120$139,166
Repatha SureclickEvolocumab114$119,619
FarxigaDapagliflozin Propanediol55$61,357
MultaqDronedarone Hcl39$50,387
VerquvoVericiguat18$28,975
BrilintaTicagrelor15$13,197
Atorvastatin Calcium687$10,441
Colchicine170$9,096
ClopidogrelClopidogrel Bisulfate472$8,507
Metoprolol Succinate436$7,398
Prasugrel Hcl103$6,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$263$513,367483 claims
NovartisEntresto$29,093$464,836352 claims
Actelion Pharmaceuticals US, Inc.Uptravi$291$257,96012 claims
Boehringer IngelheimJardiance$22,452$173,604145 claims
Johnson & JohnsonXarelto$42,396$139,166120 claims
AstraZenecaFarxiga, Brilinta$31,968$74,55470 claims
Sanofi-aventis U.S. LLCMultaq$253$50,38739 claims
MerckVerquvo$348$28,97518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Southgate

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →